BigDNA is developing a core pipeline of prophylactic vaccines directed at human infectious disease. The Company intends to develop each product to Phase I/II clinical trials and then seek partners who have the necessary infrastructure to take each candidate through late stage development and to market.
BigDNA actively seek industry and academic partners who bring complementary strengths to our development programmes. We will actively consider collaborative and/or out-licensing opportunities for our products prior to Phase I for product candidates which are non-core to our business.
How we do this can be accomplished in a number of ways: through collaborative vaccine research and development, joint ventures or active licensing of our platform technology and products. BigDNA may also be interested in speaking with partners with complementary technologies and novel antigens.
To discuss opportunities in working with BigDNA, please contact:
Tel. (+44) 131 200 6342